Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients

 

Show simple item record

dc.contributor.advisor Dandara, Collet en_ZA
dc.contributor.author Swart, Marelize en_ZA
dc.date.accessioned 2015-01-09T08:56:56Z
dc.date.available 2015-01-09T08:56:56Z
dc.date.issued 2011 en_ZA
dc.identifier.citation Swart, M. 2011. Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients. University of Cape Town. en_ZA
dc.identifier.uri http://hdl.handle.net/11427/11835
dc.description Includes abstract. en_ZA
dc.description Includes bibliographical references (leaves 82-96). en_ZA
dc.description.abstract Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug transporter ABCB1. Genetic variability in the above genes may contribute to differences in EFV plasma concentrations which affect the levels of viral suppression as well as development of side effects in patients. The aim of this project was to evaluate the effects of the different genetic polymorphisms on EFV plasma concentration levels in HIV/AIDS patients receiving first-line antiretroviral treatment (ART) containing EFV. en_ZA
dc.language.iso eng en_ZA
dc.subject.other Medicine en_ZA
dc.title Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients en_ZA
dc.type Thesis / Dissertation en_ZA
uct.type.publication Research en_ZA
uct.type.resource Thesis en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Department of Medicine en_ZA
dc.type.qualificationlevel Masters en_ZA
dc.type.qualificationname MSc en_ZA
uct.type.filetype Text
uct.type.filetype Image


Files in this item

This item appears in the following Collection(s)

Show simple item record